Matrix Metalloproteinase-13 Can Be Used As an Independent Diagnostic and Prognostic Marker for Breast Carcinoma
Matrix Metalloproteinase-13 As An Independent Diagnostic And Prognostic Marker
DOI:
https://doi.org/10.70284/njirm.v8i2.1190Keywords:
Metalloproteinase-13; breast cancer; cancer antigen 125, cancer antigen15.3.Abstract
Background & Objectives: Matrix Metalloproteinase-13(MMP-13) or Collagenase3 overexpresses in breast carcinoma and promotes tumor progression. Therefore, this study aims to investigate the clinical significance of serum matrix metalloproteinase-13 levels in various stages of breast carcinoma. Methods: The study was conducted in the Department of Biochemistry, G. R. Medical College, Gwalior using the Case-control study design. Total 235 human subjects were taken in the study. Out of which 100 normal age matched healthy subjects were considered as controls and 135 breast cancer patients. Serum levels of MMP-13 were estimated by ELISA technique while CA 15.3 and CA 125 levels by ELFA technique. Biochemical parameters – Alkaline Phosphatase, Acid Phosphatase and Calcium levels were determined by using fully automated analyzer using commercially available kits according to manufacturer instructions. Hematological parameters were determined by using Sysmex automated analyzer. Independent sample t- test and one-way ANOVA in combination with Tukey HSD along with ROC curve analysis was done for evaluating results. Results & Conclusion: Serum levels of MMP-13 were significantly higher (p<0.001) in breast cancer subjects as compared to controls. MMP-13 was found highly sensitive (100%) and specific (92.50%) with p<0.001 when compared with other tumor markers and biochemical parameters. So, MMP-13 can be used as an independent diagnostic and prognostic marker for breast carcinoma [Shrivastava S NJIRM 2017; 8(2):15-19]
References
2. Benson CS, Babua SD, Radhakrishnab S, Selvamurugnac N, Sankara BR. Expression of matrix metalloproteinases in human breast cancer tissues. Dis Markers. 2013; 34: 395–405.
3. Pivetta E, Scapolan M, Pecolo M, Wasserman B, Rumeileh IA, Balestreri L, et al. MMP-13 stimulates osteoclast differentiation and activation in tumor breast bone metastases. Breast Cancer Res. 2011; 13:105-120.
4. Freije JM, Itza ID, Balbin M, Sanchez LM, Blascon R, Toliviall J, et al. Molecular Cloning and Expression of Collagenase-3, a Novel Human Matrix Metalloproteinase Produced by Breast Carcinoma. J. Biol. Chem 1994; 269(24): 16766-16773.
5. Spivak JL, Gascon P, Ludwig H.Anemia management in oncology and hematology. The Oncologist.2009; 14(1):43-56.
6. Ali LO. Study effect of Breast Cancer on Some Hematological and Biochemical Parameters in Babylon Province, Iraq. IOSR-JPBS.2014; 9(3):20-24.
7. Ufelle SA, Ukaejiofo EO , Neboh EE , Achukwu PU , Ikekpeazu EJ , Maduka IC, et al. Some hematological parameters in pre- and post-surgery breast cancer patients in Enugu, Nigeria. Int J Cur Bio Med Sci. 2012; 2(1): 188-190.
8. Moraes SP, Cunha A, Neto JAR, Barbosa H, Roncalatto CAP, Duarte RF. Modelo experimental de tumor de Walker. Acta Cir Brass 2000; 15:1.
9. Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997; 90:1345–64.
10. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver diseases. Dig Dis Sci. 1988a; 33:1601–1614.
11. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver. Dig Dis Sci. 1988b; 33:1601–1614.
12. Friedman LS, Martin P, Munoz SJ. Liver function tests and the objective evaluation of the patient with liver disease. In: Zakim D, Boyer TD (eds) Hepatology: a textbook of liver disease. WB Saunders, Philadelphia, pp 791–833; 1996.
13. Uria JA, Stahle-Backdahl M, Seiki M, Fueyo A and Lopez-Otin C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal epithelial cell interactions. Cancer Res.1997; 57: 4882–8.
14. Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. APMIS.1999; 107:45-53.
15. Perey L, Hayes DF, Maimonis P, Abe M, O’Hara C, Kufe DW. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res.1992; 52:2563-8.
16. Chang HJ, Yang MJ, Yang YH, Hou MF, Hsueh EJ, Lin SR.MMP13 is potentially a new tumor markerbreast cancer diagnosis. Oncol Rep. 2009; 22: 1119-1127.
17. Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, et al. Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis. 2000; 18:171-178.
18. Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, et al. Tumor-derived Matrix Metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer. 2008; 8:83-93.
19. Shah M, Huang D, Blick T, Connor A, Reiter LA, Hardink JR, et al. An MMP13-Selective Inhibitor Delays Primary Tumor Growth and the Onset of Tumor-Associated Osteolytic Lesions in Experimental Models of Breast Cancer. PLoS ONE. 2012; 7(1):29615.
20. Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR et al.Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res.2001; 61: 7091-7100.
Conflict of
